Přihlášení

Přihlášený uživatel: . Nejste to Vy? Přihlašte se pod svým e-mailem.

Zadejte prosím své heslo do proLékaře.cz, abychom ověřili, že jste to opravdu Vy.

 
Aktuální číslo
Archiv čísel
Informace o časopisu
Redakční rada
Redakce
Předplatné
Pokyny pro autory a recenzenty
Kontakt
 

SUCCESSFUL SOFOSBUVIR TREATMENT WITH RIBAVIRIN DOSE REDUCTION FOR CHRONIC HEPATITIS C VIRUS GENOTYPE 2 INFECTION IN A PATIENT WITH ULCERATIVE COLITIS: A CASE REPORT

Autoři: Yuki Ohta1, Tatsuo Kanda1*, Tatsuro Katsuno1, Shin Yasui1, Yuki Haga1, Reina Sasaki1, Masato Nakamura1, Shuang Wu1, Shingo Nakamoto2, Makoto Arai1, Osamu Yokosuka1

Autoři - působiště: 1Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan., 2Department of Molecular Virology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

Článek: BMC Gastroenterology 2016, 16:66
doi: 10.1186/s12876-016-0480-x
Kategorie: Case report
Počet zobrazení článku: 49x

Specializace: gastroenterologie a hepatologie infekční lékařství
uzamčeno uzamčeno

Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report

© 2016 The Author(s).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0480-x

Souhrn


 
 
zobrazit obsah  zobrazit obsah  
 
 

© 2016 The Author(s).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: http://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-016-0480-x

Summary

Background:
Ulcerative colitis is a lifelong, immunologically mediated disease. Direct-acting antivirals (DAAs) are now available for the treatment of chronic hepatitis C virus (HCV) infection. An interferon-free regimen appears useful, safe and effective for many patients for whom interferon-based treatment is contraindicated.

Case presentation:
We studied a 56-year-old treatment-naïve Japanese man with chronic HCV genotype 2b infection who had ulcerative colitis. This patient was treated with sofosbuvir and ribavirin for 12 weeks. During treatment, diarrhoea and bloody faeces were frequent. After ribavirin was reduced to 400 mg daily, these symptoms decreased. Finally, the patient achieved a sustained virologic response 12 weeks after the stoppage of the treatment.

Conclusion:
Clinicians should pay careful attention to the ribavirin dose in the treatment of certain HCV patients with inflammatory bowel disease who are receiving sofosbuvir plus ribavirin.

Keywords:
Case report, Direct-acting antiviral (DAA), Hepatitis C virus (HCV), Interferon-free, Ribavirin, Ulcerative colitis

 

Hodnocení článku

Ohodnoťte článek:     2,4/5, hodnoceno 14x
 
 

Kreditovaný kurz

 

Inhibitory protonové pumpy (IPP)

Autor kurzu: MUDr. Rastislav Husťak
Kurz je ohodnocen 4 kredity ČLK

 
 
 
 
 
 
 

nejčtenější články